BKYI — Q2 2026 Financial Report Analysis

License sales up 53%, but an inventory write-back did most of the margin work

BIO-key International sells fingerprint-based login and identity software (its PortalGuard platform) plus the fingerprint scanners that go with it, mostly to banks, governments and universities. In the second quarter of 2026 (April–June), revenue rose 13% to $1.92 million and the net loss roughly halved to $577,000. The driver of the revenue gain was software licenses, which rose 53% to $1.23 million as several new customers deployed. The driver of the profit improvement was different: $703,050 of the quarter's gross profit came from reversing a write-down on scanner inventory the company had already written off, not from this quarter's selling.

At a glance

• License revenue $1.23M, +53%: licenses (the right to use the software, BIO-key's highest-margin line) were 64% of revenue, up from 48% a year earlier, which is the genuinely positive trend in the quarter.
• Gross margin 87.2% reported, 50.6% underlying: take out the inventory write-back and the share of revenue left after direct costs fell from 56.3% to 50.6%; the headline margin overstates how profitable the quarter's sales were.
• Cash $1.38M at June 30, down from $2.69M in December: the company says it needs about $750,000 a month to operate and carries a going-concern warning, so it raised about $2.5M from warrant exercises in August and has kept paying debt in new shares.

The numbers

Per-share figures reflect the 1-for-10 reverse stock split effective April 30, 2026. For the first half (January–June), revenue rose 23.0% to $4.07 million and the net loss narrowed to $781,889 from $1.90 million.

What drove the quarter

Licenses carried the top line. The 10-Q attributes the $423,258 license increase to "several new customers" deploying new licenses. Licenses cost very little to deliver — the cost of license fees was $74,972 against $1.23 million of license revenue — so every extra dollar here falls almost straight to gross profit. The earnings release ties the new business to government, defense and banking customers outside the US: the Central Bank of Jordan's national biometric authentication project, a Portuguese national security agency, and an education-sector partnership in Saudi Arabia.

Hardware fell, and a big order slipped. Scanner sales dropped 19% to $459,641. The release says about $0.8 million of hardware revenue that management expected in Q2 was delayed by the customer and is now expected in the second half. A year earlier, Q2 included one large deployment from a long-term customer.

Services shrank. Recurring maintenance and support revenue fell 16% to about $227,000, which the company puts down to the timing of contract renewals; one-off customization work fell from about $51,000 to about $4,000. Recurring revenue shrinking while licenses grow is worth watching: new license customers should eventually add to support revenue, not subtract from it.

Costs came down modestly. Selling, general and administrative expense fell 7% to $1.56 million on lower administration and professional fees, partly offset by one-time reverse-split costs and higher accrued audit and tax expense. R&D was flat at $640,418.

What the headline numbers hide

• The inventory write-back. BIO-key bought about $2.1 million of fingerprint scanners for projects in Nigeria that were delayed, and wrote that inventory down to nearly zero (a "reserve" — an accounting charge taken when stock may never sell at cost). When some of those units are sold, the earlier charge is reversed and shows up as a negative cost. That reversal was $703,050 in Q2 2026 versus $277,415 in Q2 2025. Without it, gross profit was $970,990, up just 1.6% from $955,312, and the operating loss was about $1.23 million, only about 9% better than the year-ago $1.36 million on the same basis. The cash from those scanners is real, but the profit was largely booked in earlier years when the write-down was taken.
• Cash burn is bigger than the loss. Operating activities used $1.20 million of cash in the first half against a reported net loss of $781,889. The write-back added to profit without adding new cash, and receivables grew.
• Receivables are growing faster than sales and are concentrated. Accounts receivable (money customers owe) rose 42% since December to $1.73 million, while first-half revenue rose 23%. Two customers account for 74% of receivables, up from 43% at year-end, and two customers made up 52% of Q2 revenue. A single slow payer would show up quickly in cash.
• Loss per share improved partly because there are more shares. The net loss shrank 51%, but loss per share shrank 72% because the average share count rose 78% after 2025's warrant exercises and debt-for-share exchanges. Each share is a smaller slice, not a more profitable one.
• An error in the 10-Q's own commentary. The MD&A says first-half hardware sales "increased 186%." The income statement shows $990,898 against $804,627, which is an increase of 23%. This report uses the income-statement figure.
• Below the operating line, a small tailwind. Loan-fee amortization fell to $20,833 from $60,000 as older debt was paid off; interest expense was about flat at $27,000. No income tax was booked in either year.

Funding: the real story around this filing

The 10-Q says plainly that the company "does not have enough cash for twelve months of operations," which is why a going-concern disclosure (a formal warning that the company may not be able to keep operating without new money) appears in the notes. BIO-key also had a rough first half on the listing front: Nasdaq suspended trading in the stock from May 13 over the $1.00 minimum bid price and late filings (the 2025 10-K came in June and the Q1 10-Q on June 22). After the 1-for-10 reverse split and an appeal, trading resumed on July 8.

Since the quarter ended, the company has:

• Raised about $2.5 million (August 11) by persuading an existing investor to exercise 618,334 warrants at a cut price of $4.06 (down from $10.20), in return for 1,236,668 new warrants at $4.06. Management says the cash balance rose to over $4.5 million after the deal. Issuing shares under those new warrants needs shareholder approval; the vote was adjourned on October 2 and is due to reconvene on October 30, 2026.
• Paid off its 2025 secured note entirely in stock. $350,000 was exchanged for 81,100 shares in July–August, and the remaining $416,316 for 247,805 shares on September 29 (8-K filed October 2). The implied exchange price fell from about $4.62 a share in July to about $1.68 in September — the later exchanges bought down the debt with far more shares per dollar.

Shares outstanding went from 1,087,360 at June 30 to 1,436,344 on August 11, and the September exchange added another 247,805. That is more than 50% dilution in about three months, before any of the new warrants are exercised. The upside is that the company now has no secured debt to service.

Did management's expectations hold up?

This is the first BIO-key report on this site, so there is no earlier read of ours to check. The nearest test is management's own: the release says Q2 "fell short of our expectations" because the roughly $0.8 million hardware order it expected in the quarter didn't ship. Revenue also fell about 10% from Q1 2026's $2.15 million, so the second quarter was a step back on a sequential basis even though it beat last year.

Takeaway: The license business is growing quickly — up 53% and now nearly two-thirds of revenue — but the halved loss leans on writing back old inventory charges; on an underlying basis gross profit was flat and the operating loss improved only about 9%. With under a year of cash on hand before the August raise and the share count up by more than half since June, BIO-key's results matter less right now than whether the delayed hardware order and the new EMEA contracts arrive before the next financing is needed.

Outlook

Management "targets revenue growth and profitability" for the second half of 2026, supported by the delayed hardware order (now expected by year-end) and government and banking projects in Europe, the Middle East and Africa. Note that the delayed order is fully reserved inventory: if it ships, it would carry close to 100% gross margin through another reserve reversal, so a profitable second half is plausible on paper even without improvement in the underlying cost structure.

What to watch in the Q3 report (due around mid-November 2026):

1. Whether the ~$0.8M hardware order shipped and how much of the quarter's profit again comes from reserve reversals versus new sales.
2. License revenue staying above $1 million a quarter — the clearest sign that the new EMEA customers are repeat business, not one-off deals.
3. Recurring maintenance revenue turning back up, and receivables from the two large customers being collected.
4. The October 30 shareholder vote on the 1.24 million warrant shares, and whether further equity raises follow. With a ~$750,000 monthly cost base against quarterly revenue around $2 million, the company remains dependent on new capital until sales grow substantially.